FDA accepts for review the supplemental Biologics License Application for inhaled insulin (Afrezza) in children and adolescents aged 4-17 years living with diabetes – MannKind
MannKind Corporation announced that the FDA has accepted the supplemental biologics license application (sBLA) seeking approval for Afrezza (insulin human) Inhalation Powder in children and adolescents living with… read more.
